Joseph Kim serves as a Senior Advisor in Clinical Development Innovation at Lilly, focusing on developing and implementing innovative patient engagement solutions. He has spent over 15 years in the Pharma industry utilizing a unique approach that integrates his experiences working for Sponsors such as Shire and Merck, CROs, and technology vendors.
Joseph has a robust combination of experience that includes early and late phase clinical research, and a well known history of innovation in the clinical research industry, recognized as one of “20 Innovators Changing the Face of the Clinical Trials Industry” by CenterWatch in 2013. He holds a BS in Molecular Biology from Lehigh University and an MBA from Villanova. He can be reached at firstname.lastname@example.org and on Twitter.
Tell us a little bit about yourself and how you got started in clinical research.
For starters, you should know that I did not come to clinical research through any natural career path. In fact, I had two other careers as a social worker and high school science teacher before landing in clinical research. My first role was as an entry level data manager. Quite comfortable with trying things on and pivoting quickly, my instinct was, “This isn’t for me either.” Given that I worked for a large pharma company (Merck), I was able to quickly learn about other roles and try them on too. My next move was as a garden variety study manager in psychiatric research. This was the old model, where it was you and a medical monitor doing everything from writing the protocol, to selecting sites, to reviewing data, to paying grants.
Reindeer Beagle by Mark Evans is licensed under CC-BY-2.0
Thank you to everyone who has made 2014 such a wonderful year! We have thoroughly enjoyed the conversations with you all and truly value your perspective. The Lilly Clinical Open Innovation (LCOI) team looks forward to continued interaction with you in 2015.
As we bring this year to a close, we’ve had some time to review our recent work, some of which we previously shared here on our blog. We sponsored a Patient Engagement App Challenge, which eventually led to the LVJJ website. The LVJJ website is a pilot project to improve how we present information to patients and caregivers on study websites. We’ve also progressed on our target profiles project, which is aimed at building a consistent framework for clinical trial eligibility criteria. And we created the Lilly Innovation Site Advocacy Group, providing us with access to great feedback from research sites.
We’re privileged to be working with Rahlyn Gossen, founder of Rebar Interactive, a digital strategy consultancy serving the clinical research industry. Rebar Interactive creates empowering (and award-winning) digital experiences for patients and professionals. Rahlyn’s digital marketing expertise spans a variety of areas, including search, social media, and mobile. Her work is infused with a patient-centric perspective, honed during Rahlyn’s time as a clinical research coordinator.
Rahlyn publishes a widely-read clinical trial blog and newsletter focusing on digital strategy, the patient experience, and innovation. The same topics are explored in 140 characters or less on Rebar Interactive’s Twitter account. Rahlyn also serves on the editorial advisory board of Applied Clinical Trials. Rahlyn is a proud New Orleanian and a connoisseur of cute online animal videos, particularly those of the feline variety.
Tell me a little bit about yourself, and the path you’ve been on to make clinical research better.
The LVJJstudy.com website is a pilot project to improve how we inform patients about clinical trials.
At Lilly COI we spend plenty of time exploring the future of clinical trials. We continue to explore clinical trial matching, Internet-based studies, mobile health in trials, and other possibilities. Though we are excited by these possibilities, we also know that it will take some time for possibilities to fully morph into practicalities. Technologies need to improve, regulatory questions need to be answered, and clinical trial models need to evolve. Meanwhile, patients are in great need of an improved clinical trial experience today. We can’t ask patients to wait on a convergence of ideal conditions, especially when there are feasible improvements that we can make now.